Nuevolution, Almirall deal

Nuevolution granted Almirall exclusive, worldwide rights to Nuevolution's RAR-related orphan receptor C thymus-specific isoform (RORgamma2; RORgammaT) inhibitor program to identify and develop small molecules against inflammatory skin diseases and psoriatic arthritis. Nuevolution retains rights to the program outside of the licensed field. Nuevolution will receive €11.2 million ($11.8 million) up front and is eligible for up to €172 million ($181.8 million) in development and regulatory milestones and up to €270 million ($285.3 million) in sales milestones, plus tiered royalties. Almirall is responsible for all further development and commercialization...